The present study demonstrates a way forward to establish a feasible, reliable and manageable active pharmacovigilance system in a resource-limited setting by taking advantage of existing monitoring platforms such as HDSS.
The combination of pemetrexed plus cisplatin followed by surgery and hemithoracic radiation is feasible and has a manageable toxicity profile in carefully selected patients.
Lapatinib 1,000 mg with nab-paclitaxel 100 mg/m IV is feasible with manageable and predictable toxicity and an ORR of 53 % comparing favorably with other HER2-based combinations in this setting.
Recently, a phase II clinical trial in hepatocellular carcinoma (HCC) has suggested that the combination of sorafenib and 5-fluorouracil (5-FU) is feasible and side effects are manageable.
Such approach is only feasible if there exists an explicit and manageable representation of Φ for the kernel at hand.
Our analyses show that the combination of BV with the XELIRI regimen is feasible with manageable toxicity, and that is associated with a promising efficacy in terms of PFS, ORR and OS in previously untreated mCRC.
In conclusion, we demonstrated that preoperative XELOX followed by CAPOX-RT is feasible with manageable toxicity and results in encouragingly high rates of pCR, R0 resection, sphincter preservation and tumour downstaging in patients with locally advanced rectal cancer.
The C-BOP/BEP schedule was feasible in a multicentre setting with predictable and manageable short-term toxicity without any toxic death.
Regarding the efficacy and safety in our clinical trial, the PFS of the nab-paclitaxel with S-1 combination therapy was longer than the nab-paclitaxel monotherapy (21.0 and 12.9 months, respectively), and the therapy was feasible, with manageable toxicities.
